Aurobindo’s debut in Botswana is with 9 products in one go

RELATED NEWS Aurobindo receives 7th approval from MCC South Africa Aurobindo’s tally of USFDA approved cephs goes up Aurobindo Pharma Q3 net surges to Rs 60.1cr Aurobindo bags one more cephalosporin from USFDA ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 25/05/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is delighted to announce that DRU (Drugs regulatory unit) of Botswana has registered nine of its ARV products at a time.

 

They are as follows

 

PRODUCT              Class

Lamivudine and

Zidovudine tablet      NRTI

 

Zidovudine oral solution

50mg/5ml                  NRTI

 

Nevirapine Oral

Suspension 50mg/ml  NNRTI

 

Lamivudine oral

solution 10mg/ml     NRTI

 

Nevirapine 200mg tablet  NNRTI

 

Stavudine 30mg

Capsules                NRTI

 

Stavudine 40mg

Capsules               NRTI

 

Lamivudine 150mg

Tablets                  NRTI

 

Lamivudine 300mg

Tablets                  NRTI

 

The products are used extensively in the management of HIV positive patients. Botswana is a key market for ARVs and hence these registrations with the authorities would help Aurobindo to consolidate its position in the said market.

 

Sourced From: Aurobindo Pharma Limited